Practical approach to management of chronic lymphocytic leukemia

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F16%3A10326696" target="_blank" >RIV/00179906:_____/16:10326696 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11150/16:10326696

Result on the web

<a href="http://dx.doi.org/10.5114/aoms.2016.55424" target="_blank" >http://dx.doi.org/10.5114/aoms.2016.55424</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.5114/aoms.2016.55424" target="_blank" >10.5114/aoms.2016.55424</a>

Result language

angličtina

Original language name

Practical approach to management of chronic lymphocytic leukemia

Original language description

Revolutionary progress has recently changed the landscape of chronic lymphocytic leukemia (CLL). Powerful prognostic factors, especially p53 mutation and/or deletion and IGHV mutation status, have refined individual patient prognosis. Purine analogs and monoclonal antibodies paved the way from palliative treatment to chemoimmunotherapy capable of eradication of minimal residual disease and prolongation of survival. Obinutuzumab (GA-101) and ofatumumab have been recently approved for the treatment of comorbid patients. Bendamustine is available for first-line treatment of patients ineligible for fludarabine, cyclophosphamide, and rituximab (FCR). High-dose glucocorticoids combined with rituximab represent a promising option for refractory CLL; ofatumumab is approved for fludarabine-and alemtuzumab-refractory patients. Allogeneic stem cell transplantation is the only curative option but is feasible in a highly selected group of patients only. The novel small molecule inhibitors ibrutinib and idelalisib have been recently approved for relapsed/refractory CLL This review provides practical advice for diagnosis, prognostication and treatment of CLL

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

<a href="/en/project/NT13412" target="_blank" >NT13412: Complex assessment of microenvironment and its impact on clinical course of chronic lymphocytic leukemia.</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2016

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Archives of Medical Science

ISSN

1734-1922

e-ISSN

—

Volume of the periodical

12

Issue of the periodical within the volume

2

Country of publishing house

PL - POLAND

Number of pages

9

Pages from-to

448-456

UT code for WoS article

000374510200028

EID of the result in the Scopus database

2-s2.0-84963768974